Key Points
- BDX EVP Michael Feld sold 75 shares on May 26 at an average price of $147.35, totaling about $11,051. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and Feld still holds 21,084 shares.
- The company recently beat quarterly expectations, reporting EPS of $2.90 versus $2.77 expected and revenue of $4.71 billion versus $4.67 billion expected. Revenue rose 5.2% year over year, and management guided FY2026 EPS to $12.52–$12.72.
- BDX also announced a quarterly dividend of $1.05 per share, payable June 30 to shareholders of record on June 9. That implies an annualized dividend of $4.20 and a yield of 2.8%.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 75 shares of the business's stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $147.35, for a total value of $11,051.25. Following the sale, the executive vice president owned 21,084 shares of the company's stock, valued at approximately $3,106,727.40. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Feld also recently made the following trade(s):
- On Monday, April 27th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $151.94, for a total value of $11,243.56.
- On Thursday, February 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $181.84, for a total value of $13,638.00.
Becton, Dickinson and Company Trading Down 0.3%
Becton, Dickinson and Company stock opened at $147.38 on Thursday. The business has a 50-day simple moving average of $152.11 and a two-hundred day simple moving average of $177.44. The company has a market cap of $40.61 billion, a P/E ratio of 37.31, a P/E/G ratio of 10.46 and a beta of 0.22. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company's payout ratio is currently 106.33%.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Activest Wealth Management grew its stake in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 97 shares during the period. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $25,000. Steph & Co. lifted its holdings in Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 65 shares in the last quarter. SHP Wealth Management purchased a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $26,000. Finally, Prosperity Bancshares Inc purchased a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. 86.97% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on BDX shares. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. JPMorgan Chase & Co. cut their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating for the company in a research note on Tuesday, February 10th. TD Cowen cut their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a "hold" rating for the company in a research note on Monday, May 4th. Zacks Research upgraded Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research note on Friday, April 10th. Finally, Evercore boosted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $184.86.
Get Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Company Profile
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
